Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2018-02-09 Annual Report
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
2017年年度报告
Annual Report Classification · 100% confidence The document is titled '2017 年年度报告' which translates to '2017 Annual Report'. It contains detailed sections typical of an annual report such as company overview, financial data, business overview, management discussion and analysis, risk factors, and audit opinions. It includes audited financial statements, profit distribution plans, and comprehensive business and financial information for the fiscal year 2017. The presence of an audit report with an unqualified opinion from Beijing Xinghua CPA firm further supports this classification. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document is the official yearly report covering company activity and full financial performance, fitting the definition of an Annual Report (10-K). FY 2017
2018-02-09 Chinese
独立董事关于公司2018年日常关联交易预计的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the company's 2018 anticipated related party transactions. It references compliance with company law, stock exchange listing rules, and internal company regulations. The document is a formal opinion or statement rather than a full financial report or audit. It does not contain financial statements or detailed financial data. It is not an announcement of a meeting or voting results, nor is it a management report or earnings release. The document is a regulatory compliance statement related to governance and internal controls on related party transactions. Given its nature and length (558 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and attestation documents that do not fit other specific categories.
2018-02-09 Chinese
2017年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '2017 年度内部控制审计报告' which translates to '2017 Internal Control Audit Report'. It is an audit report on the effectiveness of internal control over financial reporting for the fiscal year ending December 31, 2017. The text includes references to auditing standards and responsibilities of the company and auditors, typical of an audit report. The document length is 1141 characters, which is short but contains substantive audit opinion content rather than just an announcement or certification. Therefore, it is classified as an Audit Report / Information (AR).
2018-02-09 Chinese
董事会审计委员会2017年度履职报告
Management Reports Classification · 95% confidence The document is titled as the "2017年度履职报告" (2017 Annual Performance Report) of the Board Audit Committee of 哈药集团股份有限公司. It details the committee's composition, meetings held during 2017, their oversight of external and internal audits, review of financial reports, and evaluation of internal controls. The content is a report on the audit committee's activities and oversight related to the company's audit and internal control processes for the year 2017. It is not a full annual report (10-K), nor is it a standalone audit report (AR) such as an auditor's opinion or audit results alone. Instead, it is a management or committee report on audit-related governance and activities. This fits best under the category of Management Reports (MDA), which includes management's detailed explanation of financial results, business trends, and outlook, including oversight activities. The document length is 2591 characters, which is relatively short but contains substantive content about audit committee activities rather than just an announcement or certification. Therefore, the classification is MDA with high confidence.
2018-02-09 Chinese
2017年度财务报表审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "年度财务报表审计报告" which translates to "Annual Financial Statement Audit Report." It contains detailed audit opinions, audit basis, key audit matters, management and governance responsibilities, and extensive financial statements including consolidated balance sheets as of December 31, 2017. The presence of detailed financial data, audit procedures, and auditor's opinion indicates this is a standalone audit report rather than a full annual report or an announcement. The document length is substantial (15,000 characters), and it includes substantive financial data and analysis. Therefore, it fits the category of an Audit Report / Information (AR).
2018-02-09 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding a change in accounting policies in response to new regulations issued by the Ministry of Finance (财政部). It details the nature of the accounting policy changes, their impact on financial statement presentation, and includes opinions from the board of directors, independent directors, and the supervisory board. The document does not contain full financial statements or comprehensive financial performance data but rather explains the policy change and its implications. It is a formal announcement about accounting policy changes rather than a full annual or interim report, audit report, or earnings release. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2018-02-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.